MEDIA | 180 Markets

O Dr Paul Gavin recently spoke with Greg Lowe from 180 Markets about Avecho’s landmark agreement with Sandoz and the Company’s Phase III clinical trial for our TPM®-enhanced CBD softgel for insomnia.

During the conversation, Dr Gavin shared insights into the global opportunity beyond Australia:

“Australia now forms a really interesting deal benchmark. When I talk to the US, and the US pharmaceutical market is 30 times larger, you’ve got to be giving me around 30x if you want the rights to the US. Europe’s 20x, China’s 10x, and Japan’s 5x, so there’s a lot of territories now that we can start playing with.”

This partnership not only validates our approach, but provides the required capital to reach our interim analysis milestone without additional funding.

Watch the interview: